%0 Journal Article
%A Baccelli, Irène
%A Stenzinger, Albrecht
%A Vogel, Vanessa
%A Pfitzner, Berit Maria
%A Klein, Corinna
%A Wallwiener, Markus
%A Scharpff, Martina
%A Saini, Massimo
%A Holland-Letz, Tim
%A Sinn, Hans-Peter
%A Schneeweiss, Andreas
%A Denkert, Carsten
%A Weichert, Wilko
%A Trumpp, Andreas
%T Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients.
%J OncoTarget
%V 5
%N 18
%@ 1949-2553
%C [S.l.]
%I Impact Journals LLC
%M DKFZ-2017-00231
%P 8147 - 8160
%D 2014
%X Although luminal-type primary breast cancer can be efficiently treated, development of metastatic disease remains a significant clinical problem. We have previously shown that luminal-type circulating tumor cells (CTCs) co-expressing the tyrosine-kinase MET and CD47, a ligand involved in cancer cell evasion from macrophage scavenging, are able to initiate metastasis in xenografts. Here, we investigated the clinical relevance of MET-CD47 co-expression in 255 hormone receptor positive breast tumors by immunohistochemistry and found a 10.3- year mean overall-survival difference between MET-CD47 double-positive and double-negative patients (p<0.001) MET-CD47 co-expression defined a novel independent prognosticator for overall-survival by multivariate analysis (Cox proportional hazards model: HR: 4.1, p<0.002) and CD47 expression alone or in combination with MET was strongly associated with lymph node metastasis. Furthermore, flow cytometric analysis of metastatic patient blood revealed consistent presence of MET+CD47+ CTCs (range 0.8 - 33.3
%K Antigens, CD47 (NLM Chemicals)
%K Biomarkers, Tumor (NLM Chemicals)
%K CD47 protein, human (NLM Chemicals)
%K MET protein, human (NLM Chemicals)
%K Proto-Oncogene Proteins c-met (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:25230070
%2 pmc:PMC4226673
%R 10.18632/oncotarget.2385
%U https://inrepo02.dkfz.de/record/119599